Risk factors associated with drug therapy among elderly people with alzheimer’s disease: A cross-sectional study
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.1590/1516-3180.2019.0461.r2.19022020 http://hdl.handle.net/11449/200810 |
Resumo: | BACKGROUND: Improving knowledge and establishing strategies and policies for better patient safety are worldwide priorities. OBJECTIVE: To evaluate drug safety among elderly people with Alzheimer’s disease (AD). DESIGN AND SETTING: Cross-sectional study among elderly people within the National AD Assistance Protocol (PCDTDA/MS) who were living in the municipality of Araraquara, Brazil, in 2017. METHODS: Through interviews conducted with relatives/caregivers of elderly people with diagnoses of AD, the following variables were evaluated: comorbidities, drug therapy used, use of potentially inappropriate medications for the elderly (PIMs), presence of potentially inappropriate interactions (PIIs) and medication regimen complexity index. Factors associated with AD severity were also evaluated. Multivariate and simple logistic regressions were applied. RESULTS: 143 elderly people enrolled in PCDTDA/MS were analyzed. The majority were women (67.1%); assisted only through the public healthcare system (75.5%); polymedicated (57.4%); using at least one PIM (63.6%); presenting at least one PII (63.6%); and under drug therapy of low to medium complexity (92.2%). No semi-annual monitoring of the effectiveness of PCDTDA/MS drugs was identified. The proportion using AD drug therapy at daily doses differing from those recommended by the World Health Organization was 75.6%. However, these doses were not associated with drug risk. CONCLUSION: The data from this study raise the hypothesis that use of polypharmacy might show a correlation with severity of AD. The drug safety risk may be associated with comorbidities of the metabolic syndrome, anxiety and off-label use of PIMs, such as risperidone and quetiapine, and benzodiazepines (i.e. clonazepam and flunitrazepam). |
id |
UNSP_88649c545e7a7cd8d05f4c2c011321ea |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/200810 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Risk factors associated with drug therapy among elderly people with alzheimer’s disease: A cross-sectional studyDementiaPatient safetyPolypharmacyBACKGROUND: Improving knowledge and establishing strategies and policies for better patient safety are worldwide priorities. OBJECTIVE: To evaluate drug safety among elderly people with Alzheimer’s disease (AD). DESIGN AND SETTING: Cross-sectional study among elderly people within the National AD Assistance Protocol (PCDTDA/MS) who were living in the municipality of Araraquara, Brazil, in 2017. METHODS: Through interviews conducted with relatives/caregivers of elderly people with diagnoses of AD, the following variables were evaluated: comorbidities, drug therapy used, use of potentially inappropriate medications for the elderly (PIMs), presence of potentially inappropriate interactions (PIIs) and medication regimen complexity index. Factors associated with AD severity were also evaluated. Multivariate and simple logistic regressions were applied. RESULTS: 143 elderly people enrolled in PCDTDA/MS were analyzed. The majority were women (67.1%); assisted only through the public healthcare system (75.5%); polymedicated (57.4%); using at least one PIM (63.6%); presenting at least one PII (63.6%); and under drug therapy of low to medium complexity (92.2%). No semi-annual monitoring of the effectiveness of PCDTDA/MS drugs was identified. The proportion using AD drug therapy at daily doses differing from those recommended by the World Health Organization was 75.6%. However, these doses were not associated with drug risk. CONCLUSION: The data from this study raise the hypothesis that use of polypharmacy might show a correlation with severity of AD. The drug safety risk may be associated with comorbidities of the metabolic syndrome, anxiety and off-label use of PIMs, such as risperidone and quetiapine, and benzodiazepines (i.e. clonazepam and flunitrazepam).Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Department of Drugs and Medicines School of Pharmaceutical Sciences Universidade Estadual Paulista (UNESP)Department of Medical Sciences Universidade de Aveiro Institute of Biomedicine (iBiMED)Department of Psychobiology Universidade Federal de São Paulo (UNIFESP)Department of Drugs and Medicines Universidade Estadual Paulista (UNESP)Department of Drugs and Medicines School of Pharmaceutical Sciences Universidade Estadual Paulista (UNESP)Department of Drugs and Medicines Universidade Estadual Paulista (UNESP)CAPES: 001CNPq: 131206/2017-6FAPESP: 2013/12681-2FAPESP: 2018/07501-9CNPq: 459461/2014-1Universidade Estadual Paulista (Unesp)Institute of Biomedicine (iBiMED)Universidade Federal de São Paulo (UNIFESP)Forgerini, Marcela [UNESP]Herdeiro, Maria TeresaGalduróz, José Carlos FernandesMastroianni, Patrícia de Carvalho [UNESP]2020-12-12T02:16:41Z2020-12-12T02:16:41Z2020-05-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article216-228application/pdfhttp://dx.doi.org/10.1590/1516-3180.2019.0461.r2.19022020Sao Paulo Medical Journal, v. 138, n. 3, p. 216-228, 2020.1516-3180http://hdl.handle.net/11449/20081010.1590/1516-3180.2019.0461.r2.19022020S1516-318020200003002162-s2.0-85088490771S1516-31802020000300216.pdfScopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengSao Paulo Medical Journalinfo:eu-repo/semantics/openAccess2024-01-23T07:08:03Zoai:repositorio.unesp.br:11449/200810Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-01-23T07:08:03Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Risk factors associated with drug therapy among elderly people with alzheimer’s disease: A cross-sectional study |
title |
Risk factors associated with drug therapy among elderly people with alzheimer’s disease: A cross-sectional study |
spellingShingle |
Risk factors associated with drug therapy among elderly people with alzheimer’s disease: A cross-sectional study Forgerini, Marcela [UNESP] Dementia Patient safety Polypharmacy |
title_short |
Risk factors associated with drug therapy among elderly people with alzheimer’s disease: A cross-sectional study |
title_full |
Risk factors associated with drug therapy among elderly people with alzheimer’s disease: A cross-sectional study |
title_fullStr |
Risk factors associated with drug therapy among elderly people with alzheimer’s disease: A cross-sectional study |
title_full_unstemmed |
Risk factors associated with drug therapy among elderly people with alzheimer’s disease: A cross-sectional study |
title_sort |
Risk factors associated with drug therapy among elderly people with alzheimer’s disease: A cross-sectional study |
author |
Forgerini, Marcela [UNESP] |
author_facet |
Forgerini, Marcela [UNESP] Herdeiro, Maria Teresa Galduróz, José Carlos Fernandes Mastroianni, Patrícia de Carvalho [UNESP] |
author_role |
author |
author2 |
Herdeiro, Maria Teresa Galduróz, José Carlos Fernandes Mastroianni, Patrícia de Carvalho [UNESP] |
author2_role |
author author author |
dc.contributor.none.fl_str_mv |
Universidade Estadual Paulista (Unesp) Institute of Biomedicine (iBiMED) Universidade Federal de São Paulo (UNIFESP) |
dc.contributor.author.fl_str_mv |
Forgerini, Marcela [UNESP] Herdeiro, Maria Teresa Galduróz, José Carlos Fernandes Mastroianni, Patrícia de Carvalho [UNESP] |
dc.subject.por.fl_str_mv |
Dementia Patient safety Polypharmacy |
topic |
Dementia Patient safety Polypharmacy |
description |
BACKGROUND: Improving knowledge and establishing strategies and policies for better patient safety are worldwide priorities. OBJECTIVE: To evaluate drug safety among elderly people with Alzheimer’s disease (AD). DESIGN AND SETTING: Cross-sectional study among elderly people within the National AD Assistance Protocol (PCDTDA/MS) who were living in the municipality of Araraquara, Brazil, in 2017. METHODS: Through interviews conducted with relatives/caregivers of elderly people with diagnoses of AD, the following variables were evaluated: comorbidities, drug therapy used, use of potentially inappropriate medications for the elderly (PIMs), presence of potentially inappropriate interactions (PIIs) and medication regimen complexity index. Factors associated with AD severity were also evaluated. Multivariate and simple logistic regressions were applied. RESULTS: 143 elderly people enrolled in PCDTDA/MS were analyzed. The majority were women (67.1%); assisted only through the public healthcare system (75.5%); polymedicated (57.4%); using at least one PIM (63.6%); presenting at least one PII (63.6%); and under drug therapy of low to medium complexity (92.2%). No semi-annual monitoring of the effectiveness of PCDTDA/MS drugs was identified. The proportion using AD drug therapy at daily doses differing from those recommended by the World Health Organization was 75.6%. However, these doses were not associated with drug risk. CONCLUSION: The data from this study raise the hypothesis that use of polypharmacy might show a correlation with severity of AD. The drug safety risk may be associated with comorbidities of the metabolic syndrome, anxiety and off-label use of PIMs, such as risperidone and quetiapine, and benzodiazepines (i.e. clonazepam and flunitrazepam). |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-12-12T02:16:41Z 2020-12-12T02:16:41Z 2020-05-01 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1590/1516-3180.2019.0461.r2.19022020 Sao Paulo Medical Journal, v. 138, n. 3, p. 216-228, 2020. 1516-3180 http://hdl.handle.net/11449/200810 10.1590/1516-3180.2019.0461.r2.19022020 S1516-31802020000300216 2-s2.0-85088490771 S1516-31802020000300216.pdf |
url |
http://dx.doi.org/10.1590/1516-3180.2019.0461.r2.19022020 http://hdl.handle.net/11449/200810 |
identifier_str_mv |
Sao Paulo Medical Journal, v. 138, n. 3, p. 216-228, 2020. 1516-3180 10.1590/1516-3180.2019.0461.r2.19022020 S1516-31802020000300216 2-s2.0-85088490771 S1516-31802020000300216.pdf |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Sao Paulo Medical Journal |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
216-228 application/pdf |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1799965704338800640 |